Stock Market Reviews

MAZE (Maze Therapeutics, Inc.) News

Get the latest news, insights, and market updates on MAZE (Maze Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
  First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed
  Nov 6, 2025 - $MAZE
• Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
  SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology’s (ASN) Kidney Week, being held November 6-9 in Houston, Texas. During the meetings, Maze Therapeutics will present additional pharmacokinetic data from its Phase 1 clinical trial of MZ
  Nov 6, 2025 - $MAZE
• Maze Therapeutics to Participate in Four Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m. ETTD Cowen Immunology & Inflammation Summit; fire
  Nov 4, 2025 - $MAZE
• Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
  Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotechSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeedin
  Oct 6, 2025 - $MAZE
• Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge
  Maze Therapeutics (MAZE) gained nearly 2% today as the stock continued its surge from the past month. Shares have risen almost 78% during this period. Investors are watching to see if this momentum holds. See our latest analysis for Maze Therapeutics. Maze Therapeutics’ latest rally caps off a strong 30-day share price return of almost 79%, signaling a surge in investor interest. Looking at the past year, its overall momentum is building, helped along by recent market enthusiasm and...
  Oct 4, 2025 - $MAZE
• Maze Therapeutics, Inc. (MAZE): A Bull Case Theory
  We came across a bullish thesis on Maze Therapeutics, Inc. on deep market scan subreddit by retroviber. In this article, we will summarize the bulls’ thesis on MAZE. Maze Therapeutics, Inc.’s share was trading at $23.25 as of September 15th. MAZE’s forward P/E was 8.53 according to Yahoo Finance. Maze Therapeutics (NASDAQ: MAZE) is showing a compelling […]
  Sep 19, 2025 - $MAZE
• Maze reports positive results from Phase I trial of PKU and CKD treatment
  The primary goals of the trial focused on the safety and tolerability of SAD and MAD doses of the therapy.
  Sep 12, 2025 - $MAZE
• Takeda poaches top Lilly exec; Maze soars on early PKU drug data
  Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in court.
  Sep 12, 2025 - $MAZE
• Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
  Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective
  Sep 11, 2025 - $MAZE
• Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
  SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses. The private placement
  Sep 11, 2025 - $MAZE